Chardan Capital reiterated coverage on BiomX with a new price target

11/16/21 9:23:03 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PHGE

Date	Price Target	Rating	Analyst
11/16/2021	$16.00 → $13.00	Buy	Chardan Capital
10/19/2021	$28.00 → $16.00	Buy	Chardan Capital
10/18/2021	$20.00 → $10.00	Buy	HC Wainwright & Co.